Tranexamic acid reduces head injury-related death

  • Lancet

  • curated by Dawn O'Shea
  • UK Medical News
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Tranexamic acid within three hours of injury reduces head injury-related death, according to results from the groundbreaking Clinical Randomisation of an Antifibrinolytic in Significant Head Injury (CRASH-3) trial.

The randomised, placebo-controlled trial was carried out in 175 hospitals in 29 countries and recruited adults with traumatic brain injury (TBI) who were within three hours of injury, with a Glasgow Coma Scale (GCS) score of ≥12 or any intracranial bleeding on computed tomography scan and no major extracranial bleeding. Participants were randomly assigned 1:1 to receive tranexamic acid (loading dose 1 g over 10 min then infusion of 1 g over eight hours) or matching placebo.

Between 20 July 2012 and 31 Jan 2019, 12,737 patients with TBI were allocated to receive tranexamic acid (n=6406) or placebo (n=6331), of whom 9202 (72.2%) were treated within three hours of injury.

Among patients treated within three hours of injury, the risk for head injury-related death was 18.5 per cent in the tranexamic acid group versus 19.8 per cent in the placebo group (risk ratio [RR], 0.94; 95% CI, 0.86-1.02).

In the pre-specified sensitivity analysis that excluded patients with a GCS score of three or bilateral unreactive pupils at baseline, the risk for head injury-related death was 12.5 per cent with tranexamic acid versus 14.0 per cent with placebo (RR, 0.89; 95% CI, 0.80-1.00).

The risk for head injury-related death reduced with tranexamic acid in patients with mild-to-moderate head injury (RR, 0.78; 95% CI, 0.64-0.95) but not in patients with severe head injury (RR, 0.99; 95% CI, 0.91-1.07; Pfor heterogeneity=.030).

The risks for vascular occlusive events and seizures were similar between groups (RR, 0.98; 95% CI, 0.74-1.28 and RR, 1.09; 95% CI, 0.90-1.33, respectively).

The authors recommend that patients with TBI should be treated with tranexamic acid as soon as possible after injury.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit